质子泵抑制剂与噻吩吡啶联用的脑血管结局:系统综述与荟萃分析
结果显示,联合用药与缺血性卒中风险增加相关(RR 1.74, 95%CI 1.41-2.16, P<0.001),校正分析中卒中风险仍增加(校正HR 1.30, 95%CI 1.04-1.61, P=0.02)。结论提示PPI与噻吩吡啶联用增加缺血性卒中和复合终点风险,支持现行指南关于PPI处方精简和药物警戒的建议。
要点
- PPI与噻吩吡啶联用增加缺血性卒中风险(RR 1.74, 95%CI 1.41-2.16)。
- 校正混杂后卒中风险仍增加(校正HR 1.30, 95%CI 1.04-1.61)。
- 联用还增加卒中/心梗/心血管死亡复合终点风险(校正HR 1.23)。
核心结论
- PPI与噻吩吡啶联用增加新发缺血性卒中和卒中/心梗/心血管死亡复合终点风险。
- 研究结果支持现行指南关于PPI处方精简和药物警戒的建议,尤其对接受噻吩吡啶治疗的患者。
研究设计与样本
- 系统综述与荟萃分析,纳入随机对照试验和队列研究,检索时间从建库至2017年7月。
主要发现
- 联用PPI与噻吩吡啶者缺血性卒中风险增加(RR 1.74, 95%CI 1.41-2.16, P<0.001)。
- 联用者卒中/心梗/心血管死亡复合终点风险增加(RR 1.14, 95%CI 1.01-1.29, P=0.04)。
- 联用者心梗风险增加(RR 1.19, 95%CI 1.00-1.40, P=0.05)。
- 校正分析中,联用与卒中风险增加相关(校正HR 1.30, 95%CI 1.04-1.61, P=0.02)。
- 校正分析中,联用与复合终点风险增加相关(校正HR 1.23, 95%CI 1.03-1.47, P=0.02),但与心梗无关(校正HR 1.19, 95%CI 0.93-1.52, P=0.16)。
临床怎么用
- 对接受噻吩吡啶治疗的患者,应审慎评估PPI联用的必要性,并加强药物警戒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Pharmacokinetic and prior studies on thienopyridine and proton pump inhibitors (PPI) coadministration provide conflicting data for cardiovascular outcomes, whereas there is no established evidence on the association of concomitant use of PPI and thienopyridines with adverse cerebrovascular outcomes. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials and cohort studies from inception to July 2017, reporting following outcomes among patients treated with thienopyridine and PPI versus thienopyridine alone (1) ischemic stroke, (2) combined ischemic or hemorrhagic stroke, (3) composite outcome of stroke, myocardial infarction (MI), and cardiovascular death, (4) MI, (5) all-cause mortality, and (6) major or minor bleeding events. After the unadjusted analyses of risk ratios, we performed additional analyses of studies reporting hazard ratios adjusted for potential confounders. RESULTS: We identified 22 studies (12 randomized controlled trials and 10 cohort studies) comprising 131 714 patients. Concomitant use of PPI with thienopyridines was associated with increased risk of ischemic stroke (risk ratio, 1.74; 95% confidence interval [CI], 1.41-2.16; P<0.001), composite stroke/MI/cardiovascular death (risk ratio, 1.14; 95% CI, 1.01-1.29; P=0.04), and MI (risk ratio, 1.19; 95% CI, 1.00-1.40; P=0.05). Likewise, in adjusted analyses concomitant use of PPI with thienopyridines was again associated with increased risk of stroke (hazard ratios adjusted, 1.30; 95% CI, 1.04-1.61; P=0.02), composite stroke/MI/cardiovascular death (hazard ratios adjusted, 1.23; 95% CI, 1.03-1.47; P=0.02), but not with MI (hazard ratios adjusted, 1.19; 95% CI, 0.93-1.52; P=0.16). CONCLUSIONS: Co-prescription of PPI and thienopyridines increases the risk of incident ischemic strokes and composite stroke/MI/cardiovascular death. Our findings corroborate the current guidelines for PPI deprescription and pharmacovigilance, especially in patients treated with thienopyridines.
引用
- Malhotra K, Katsanos AH, Bilal M, et al. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. Stroke. 2018. PMID: 29339434. doi:10.1161/STROKEAHA.117.019166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。